The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Coherus Biosciences Inc

Nasdaq: CHRS
Last

(U.S.) $13.59

Today's change-0.16 -1.16%
Updated November 26 4:00 PM -5GMT. Delayed by at least 15 minutes.
 

Coherus Biosciences Inc

Nasdaq: CHRS
Last

(U.S.) $13.59

Today's change-0.16 -1.16%
Updated November 26 4:00 PM -5GMT. Delayed by at least 15 minutes.

Coherus Biosciences Inc down (U.S.)$0.16

Coherus Biosciences Inc closed lower Wednesday, dropping (U.S.)$0.16 or 1.16% to (U.S.)$13.59. Over the last five days, shares have gained 3.27%, but are currently unchanged over the last year to date. Shares have underperformed the S&P 500 by 0.00% during the last year.

Key company metrics

  • Open(U.S.) $13.77
  • Previous close(U.S.) $13.75
  • High(U.S.) $14.12
  • Low(U.S.) $13.25
  • Bid / Ask-- / --
  • YTD % change--
  • Volume55,353
  • Average volume (10-day)109,558
  • Average volume (1-month)--
  • Average volume (3-month)--
  • 52-week range(U.S.) $12.27 to (U.S.) $16.25
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$2.69
Updated November 26 4:00 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-837.98%

The data is not available to provide analysis on this topic.
Company Books

S&P TSX0.23%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2014Q1/2014Q4/2013Q2/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013Jun 30, 201306/30/2013
Revenue5431
Total other revenue--------
Total revenue5431
Gross profit--------
Total cost of revenue--------
Total operating expense23173910
Selling / general / administrative4371
Research & development1914318
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-18-14-36-9
Interest income (expense), net non-operating-1-3-50
Gain (loss) on sale of assets--------
Other--------
Income before tax-25-25-54-9
Income after tax-25-25-54-9
Income tax, total0000
Net income-25-25-54-9
Total adjustments to net income--------
Net income before extra. items-25-25-54-9
Minority interest0------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-25-25-54-9
Inc. avail. to common incl. extra. items-25-25-54-9
Diluted net income-25-25-54-9
Dilution adjustment0000
Diluted weighted average shares32323232
Diluted EPS excluding extraordinary itemsvalue per share-0.78-0.79-1.67-0.27
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.78-0.79-1.67-0.27